ICG
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Early-stage Lung Cancer
Conditions
Early-stage Lung Cancer
Trial Timeline
Oct 3, 2022 → Oct 31, 2024
NCT ID
NCT05555199About ICG
ICG is a pre-clinical stage product being developed by Johnson & Johnson for Early-stage Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05555199. Target conditions include Early-stage Lung Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05555199 | Pre-clinical | Completed |
Competing Products
9 competing products in Early-stage Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Anastrozole + Trastuzumab Deruxtecan | Daiichi Sankyo | Phase 2 | 52 |
| SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Tamoxifen alone + Tamoxifen + Aminoglutethimide | AstraZeneca | Phase 3 | 77 |
| Cyclophosphamide + Methotrexate + Fluorouracil implant + Goserelin + Tamoxifen | AstraZeneca | Phase 3 | 77 |
| ABP 234 + Pembrolizumab | Amgen | Phase 3 | 76 |
| Rotigotine | UCB | Phase 3 | 74 |
| UCB0599 + Placebo | UCB | Phase 2 | 49 |
| Rasagiline + Pramipexole | Lundbeck | Approved | 82 |
| Neratinib + Loperamide + Colesevelam | Puma Biotechnology | Phase 2 | 44 |